Glycogen Synthase Kinase-3β Expression and Phosphorylation in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis

References (25)

1. 1 El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis [DOI]
2. 2 Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B [DOI]
3. 3 The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function [DOI]
4. 4 Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells [DOI]
5. 5 Toll-like receptor–mediated cytokine production is differentially regulated by glycogen synthase kinase 3 [DOI]
6. 6 Lithium delays progression of amyotrophic lateral sclerosis [DOI]
7. 7 GSK-3: Functional Insights from Cell Biology and Animal Models [DOI]
8. 8 GSK3: A possible link between beta amyloid peptide and tau protein [DOI]
9. 9 Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model [DOI]
10. 10 Benefit of valproic acid in suppressing disease progression of ALS model mice [DOI]
11. 11 Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial [DOI]
12. 12 Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? [DOI]
13. 13 Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord [DOI]
14. 14 Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease [DOI]
15. 15 A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium [DOI]
16. 16 Glycogen Synthase Kinase-3 Is an Early Determinant in the Differentiation of Pathogenic Th17 Cells [DOI]
17. 17 Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS [DOI]
18. 18 GSK-3 mouse models to study neuronal apoptosis and neurodegeneration [DOI]
19. 19 Upregulation of GSK3β expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci) [DOI]
20. 20 Role of GSK‐3β activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene [DOI]
21. 21 GSK-3β Gene Expression in Human Postmortem Brain: Regional Distribution, Effects of Age and Suicide [DOI]
22. 22 Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese [DOI]
23. 23 The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy [DOI]
24. 24 Immunohistochemical expression of IGF‐I and GSK in the spinal cord of Kii and Guamanian ALS patients [DOI]
25. 25 Glycogen-synthase kinase-3β is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment [DOI]

Cited by 5

Showing 3 of 5 known citations — external sources report more than can currently be individually listed.

Related research

• Perception among Future Healthcare Providers about Treatment and Management of ALS — shares topic coverage
• University Students’ Attitude towards Amyotrophic Lateral Sclerosis — shares topic coverage
• Amyotrophic Lateral Sclerosis Knowledge among University Students — shares topic coverage
• Thoracic Syringomyelia in a Patient with Amyotrophic Lateral Sclerosis — shares topic coverage
• Investigating the Roles of Gut Microbiome in the Progression of Neurodegenerative Diseases: Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS) — shares topic coverage